Akero Therapeutics to Participate in Upcoming Virtual Healthcare Conferences in March
Akero Therapeutics (Nasdaq: AKRO) announced its participation in two upcoming virtual investor conferences in March 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Akero Therapeutics (Nasdaq: AKRO) announced its participation in two upcoming virtual investor conferences in March 2021. The Cowen 41st Annual Healthcare Conference is scheduled for March 2, while the 2021 H.C. Wainwright Global Life Sciences Conference will take place on March 9. The company will offer live webcasts of its presentations, which will be accessible through their investor relations website. Akero is focused on developing therapies for non-alcoholic steatohepatitis (NASH), with its lead program, EFX, currently in Phase 2 clinical trials.
Details
News Market Reaction – AKRO
The recorded move for AKRO in the trading session of this news was +1.59%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Feb. 23, 2021 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that members of its management team will participate in the following virtual investor conferences in March:
- Cowen 41st Annual Healthcare Conference on Tuesday, March 2, 2021
- 2021 H.C. Wainwright Global Life Sciences Conference on Tuesday, March 9, 2021
A live webcast, if recorded, of Company presentations and Q&A will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcasts, archived replays will be available on the Company's website.
About Akero Therapeutics
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead program, EFX, an engineered Fc-FGF21 fusion protein, is currently being evaluated in Phase 2 clinical trials as a potential treatment for NASH. Akero is headquartered in South San Francisco. Visit us at www.akerotx.com for more information.
Investor Contact:
Christina Tartaglia
212.362.1200
IR@akerotx.com
Media Contact:
Jennifer Weismann
612-716-0556
media@akerotx.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/akero-therapeutics-to-participate-in-upcoming-virtual-healthcare-conferences-in-march-301233943.html
SOURCE Akero Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.